Antibody Conjugate Therapeutics: Challenge and Potential

Antibody conjugates are a diverse class of therapeutics consisting of a cytotoxic agent linked covalently to an antibody or antibody fragment directed toward a specific cell surface target expressed by tumor cells. The notion that antibodies directed toward targets on the surface of malignant cells could be used for drug delivery is not new.

  • Antibody-Drug Conjugates Design And Development
  • Bispecific antibody conjugates in therapeutics
  • Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics
  • New Developments in Antibody-Drug Conjugates

Related Conference of Antibody Conjugate Therapeutics: Challenge and Potential

October 19-20, 2018

10th World Congress and Expo on Immunology

New York, USA
October 29-30, 2018

6th International Conference on HIV/AIDS, STDs and STIs

San Francisco, USA
November 26-27, 2018

3rd International Conference on Autoimmunity

Dublin, Ireland (Louis Fitzgerald Hotel)
December 05-06, 2018

Global Meet on Immunology, Hematology and Molecular Biology

Portugal, Lisbon
December 06-08, 2018

Annual Congress on Antibiotics and Antimicrobial Resistance

Amsterdam, Netherlands
March 04-05, 2019

10th Molecular Immunology & Immunogenetics Congress

Barcelona, Spain
March 18-19, 2019

11th Global Summit on Immunology and Cell Biology

Sydney, Australia
June 13-14, 2019 |

10th European Immunology Conference

Berlin, Germany
July 29-30 2019

6th International Conference on Parasitology & Microbiology

Amsterdam, Netherlands
November 22-23, 2019 |

World Conference on Vaccine and Immunology

Dubai, UAE

Antibody Conjugate Therapeutics: Challenge and Potential Conference Speakers

Recommended Sessions

Related Journals

Are you interested in